At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 26 enrolled
Drug / intervention
LY3819253 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19
In Brief
A Phase 1 clinical trial evaluating LY3819253 and Placebo for COVID-19. Completed, enrolled 26 participants across 11 sites.
Detailed Summary
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last about 8 weeks and may include up to 15 visits in the hospital or the home.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsAbCellera Biologics Inc.
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartMay 2020
First PostedJun 2020
Primary CompletionAug 2020
TodayJul 2026
First PostedJun 2, 2020
Enrollment StartMay 28, 2020
Primary CompletionAug 26, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.1 years ago
Interventions
LY3819253drug
Administered IV.
Placebodrug
Administered IV.